Zibotentan - Top 10 Phase III Failures

The drug: Zibotentan
The disease: Prostate cancer
The company: AstraZeneca

Earlier this year, analysts began to pay particularly close attention to AstraZeneca's late-stage development program for zibotentan, an oral prostate cancer drug that could go head-to-head with the newly approved, an enormously expensive, Provenge.

It turned out, though, that Dendreon had nothing to fear this soon. In late September AstraZeneca announced that zibotentan-a daily tablet that works by blocking the endothelin pathway, which drives the spread of cancer--flunked a Phase III test. In a tersely worded note, AstraZeneca said only that there would be no regulatory filings "at this time." AstraZeneca was also forced to release revised stats from a mid-stage study, moving the drug from positive to less-then-promising.

Two other studies for the therapy in metastatic castration-resistant prostate cancer are continuing, with more data due out in 2011. Once a drug reaches the point where it is involved in an ambitious Phase III program like this, it's very hard to stop it early.

Zibotentan - Top 10 Phase III Failures

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.